Paroxysmal Nocturnal Hemoglobinuria (PNH)
Factor B inhibitor iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria
Paroxysmal nocturnal hemoglobinuria Paroxysmal nocturnal hemoglobinuria: (pa
Paroxysmal nocturnal hemoglobinuria-related thrombosis in the era of novel therapies: a 2043-patient-year analysis
Thrombophilia is one of the principal features of paroxysmal nocturnal hemoglobinuria paroxysma
PNH from the 2024 Philadelphia Patient and Family Conference
Topic(s)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Gloria F. Gerber, MD, explains the diagnosis and treatment of PNH, or Paroxysmal Nocturnal Hemoglobinuria. Watch this session to understand what happens to patients who develop PNH, and the options for treatment of this bone marrow failure disease.
A Patient Story - from the 2024 Philadelphia Patient and Family Conference
Topic(s)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Aplastic Anemia
Living Well with Bone Marrow Failure
Myelodysplastic Syndromes (MDS)
Ellen Kalinosky describes her turbulent journey through multiple bone marrow failure diseases in this recording from the 2024 Philadelphia Patient and Family Conference.
Anem Waheed, MD, MPH
Institution
Weill Cornell Medicine
Primary Disease Area of Focus
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition
Crovalimab Crovalimab: An experimental complement inhibitor C5 monoclonal antibody.
Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria
Crovalimab Crovalimab: An experimental complement inhibitor C5 monoclonal antibody.